Hey friends, Shivang here, with Tania Rallo co-writing again. Last issue we ended with Margaret the corgi sitting at her kitchen table holding a denial letter, and a promise that we would walk through how she actually writes the appeal. Today we keep that promise. We follow her, day by day, through the whole thing. By the end you'll have a letter you can adapt, the deadlines that apply to your plan, and a clear picture of what works. We go into a lot of detail but this will help you write appeal letters that actually move the needle!
Hey there, I’m Shivang. Each week, I write in plain English about how health insurance works, why claims get denied, and how patients and healthcare teams can get paid or reimbursed.
A two-line recap if you missed Part 1
Margaret is a in her mid-fifties. She's Biscuit's mom (Biscuit is the corgi from our Medical billing 101 issue). Her mother died of ovarian cancer at 58, her aunt had breast cancer at 47, and her doctor Dr. Singh referred her for a hereditary cancer panel after a family history risk assessment put her in the high-risk category. Her insurance company, BHC, denied the test in one line: "Not medically necessary under current plan guidelines."
In Part 1 we covered the six federal rights every patient has when a claim is denied, written into 45 CFR 147.136. Today she uses them. (Highly recommend checking it out: Why you should appeal denied claims, and the rights the US government quietly gave you ).
The letter is still on the table
Margaret has read the denial letter four times. She knows what BHC said. She does not know what to do.
Here's what the letter actually looks like. The phrasing is real. Most denial letters in the US look almost exactly like this.
Read it again. There is no explanation of which guideline BHC applied. There is no mention of Margaret's family history. There is no reference to the genetic counselor. They told her HOW to appeal (portal, mail, or fax) but they did not tell her WHY the claim was denied in any way she can actually argue against.
This is why most people get stuck. The letter doesn't tell you what was wrong with the claim, so it doesn't tell you what an appeal would even need to argue. The phrasing is built to feel final. "Not medically necessary" sounds like a doctor reviewed it and said no.
Margaret's first instinct is to call Dr. Singh's office. She picks up the phone, then puts it down. In Part 1 she learned that "we'll handle the appeal" is the moment her federal rights quietly slip out of her hands. She wants to keep them.
So she opens a notebook and writes three things at the top of the page.
She writes the date of the denial letter (May 10). From this moment, she has 180 days to file an internal appeal. That is the federal deadline for most plans, written into the same regulation that gave her the rights.
She writes is the name of her plan type. Margaret has employer coverage through her old company's retiree benefits. She calls HR. They tell her it's a fully insured plan, which means state insurance regulators oversee her appeal process and the federal rules at 45 CFR 147.136 apply directly. (If they had said "self-funded," the federal rules would still apply, but the external review track would go through the federal HHS process or whatever the plan's Summary Plan Description specifies, instead of through state regulators. Self-funded plans cover about 60% of large-employer workers in the US, per KFF 2024 data. The deadlines are the same. The path is different.)
She creates a list. Three documents she needs to request from BHC before she writes a single word of an appeal. This is the part most people skip, which is exactly why most appeals fail.
The three documents
Part 1 already gave her the rights. Today she uses them. Each of the three requests below is backed by a specific federal regulation that the insurer is required to comply with.
She is going to ask BHC for:
The full medical reasoning behind the denial, in writing: Not "not medically necessary." The actual paragraph. Federal authority: 45 CFR 147.136(b)(2)(ii)(E)(3) requires the insurer to provide "the denial code and its corresponding meaning, as well as a description of the plan's or issuer's standard, if any, that was used in denying the claim." Plus 45 CFR 147.136(b)(2)(ii)(E)(2) requires the diagnosis code, the treatment code, and their meanings, on request.
The complete claim file: Every note, every internal communication, every document the medical reviewer touched. Federal authority: 45 CFR 147.136(b)(2)(ii)(C) ("full and fair review") requires the plan to provide the claimant, free of charge, with all evidence "considered, relied upon, or generated by the plan or issuer" in connection with the claim. This incorporates 29 CFR 2560.503-1(h)(2), the DOL ERISA rule that gives claimants the right to review the entire claim file.
The actual clinical policy BHC applied to her test: The whole document. Not a summary. Federal authority: 29 CFR 2560.503-1(m)(8) (incorporated into 45 CFR 147.136) defines "relevant" documents to include any "statement of policy or guidance with respect to the plan concerning the denied treatment option or benefit for the claimant's diagnosis, without regard to whether such advice or statement was relied upon in making the benefit determination." In plain English: she gets to see the rulebook, even the version of the rulebook the insurer didn't admit they were using.
She drafts a short letter requesting all three at once. Two sentences. She cites the specific regulations above so BHC knows she did the homework. She submits it through BHC's member portal (gets a confirmation case number, screenshots it) and also mails a copy certified with return receipt as her backup, because if BHC misses a deadline later, the postal receipt is her proof. Total cost: about $10.
On May 12 the request goes out.
The full medical reasoning behind the denial, in writing. Not "not medically necessary." The actual paragraph. (Right 1.)
The complete claim file. Every note, every internal communication, every document the medical reviewer touched. (Right 2.)
The actual clinical policy BHC applied to her test. The whole document. Not a summary. (Right 3.)
Two weeks pass
On May 26 a thick envelope arrives from BHC. Inside are three things: a one-page memo with the medical reviewer's reasoning, a stack of papers labeled "Claim File," and a 14-page document titled "Hereditary Cancer Testing Criteria, Version 7.3."
What Margaret finds in the documents
Three things jump out:
The reviewer's note doesn't mention her family history: The whole note is one paragraph long. It says her case doesn't qualify because she doesn't have a personal history of cancer. Her mother, her aunt, and her grandmother are not mentioned anywhere.
BHC's policy requires a personal history for some categories of testing: But not all. There's a section for family-history-based testing further down, with its own criteria. The reviewer's note never references it.
The policy doesn't mention the USPSTF: This is the big one. The U.S. Preventive Services Task Force is a federal panel of medical experts that decides which preventive services are officially recommended. The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer with an appropriate brief familial risk assessment tool. Women with a positive result should receive genetic counseling and, if indicated, genetic testing. This carries a "B" recommendation.
Why does that "B" matter? Under Section 2713 of the Affordable Care Act, non-grandfathered health plans must cover preventive services that get a Grade A or B from the USPSTF, with no copay, no coinsurance, no deductible, when provided in-network.
Quick explainer: USPSTF Grade A and Grade B
The U.S. Preventive Services Task Force grades preventive services on a letter scale based on the strength of the evidence and the size of the benefit.
Grade A means there is high certainty that the service has a substantial net benefit. The USPSTF strongly recommends it.
Grade B means there is high certainty of a moderate benefit, or moderate certainty of a moderate-to-substantial benefit. The USPSTF recommends it.
Both Grade A and Grade B services must be covered by most health plans with no cost-sharing under Section 2713 of the ACA. Examples of Grade A and B services include colon cancer screening, blood pressure screening, and (in Margaret's case) BRCA risk assessment and genetic testing for women with a qualifying family history.
Grades C, D, and I (insufficient evidence) are NOT required to be covered without cost-sharing under the ACA.
Margaret had a family history of ovarian and breast cancer in three first- and second-degree relatives. She had a positive result on the risk assessment Dr. Singh did. Her doctor and her counselor were both in-network. By the federal preventive services standard, this test is supposed to be free.
That is the gap. BHC's policy is narrower than the federal floor. And the reviewer applied an even narrower version of BHC's policy than what's written down. She has her argument.
Margaret writes the letter
Here is the letter Margaret writes. We'll go through it in pieces and explain what each piece is doing and why.
A. The Opening
Margaret T. Corgi Member ID: BHC-44820173 Claim Number: 87654321 Date of Denial: May 10, 2026
BHC Insurance Company, Appeals Department (Address from denial letter)
Re: Formal appeal of denial, Claim 87654321, Hereditary Cancer Panel
June 9, 2026
To the Appeals Reviewer,
I am writing under 45 CFR 147.136 to formally appeal the denial of coverage for the hereditary cancer panel ordered by my physician, Dr. Singh, on April 28, 2026. The denial letter stated the test was "not medically necessary under current plan guidelines." After reviewing the complete claim file and the clinical policy your reviewer applied, I disagree with the decision for the reasons below.
What this opening does. Three things in five lines. It tells BHC she knows the regulation by name. It names the exact denial language so they know she read it. And it tells them she has already read the file and the policy, which signals she did the homework most patients don't do.
B. Family medical history
I am a 54-year-old woman with the following family history of cancer:
Mother: ovarian cancer at 58
Maternal aunt: breast cancer at 47
Maternal grandmother: breast cancer at 62
On April 14, 2026, Dr. Singh administered a family history risk assessment. I scored in the high-risk category and was referred to a genetic counselor, who recommended a hereditary cancer panel (BRCA1, BRCA2, PALB2, CHEK2, ATM).
The basis for my appeal
My appeal rests on three points.
First, the USPSTF Grade B recommendation applies to my situation. The U.S. Preventive Services Task Force recommends BRCA-related risk assessment, genetic counseling, and genetic testing for women with a family history of breast, ovarian, tubal, or peritoneal cancer. This is a Grade B recommendation. Under Section 2713 of the ACA, non-grandfathered health plans must cover Grade A and B preventive services without cost-sharing when provided in-network. My family history meets the criteria.
Second, the clinical policy your reviewer applied is narrower than the federal preventive services requirement. The policy requires a personal history of cancer for several categories of hereditary testing. I do not have a personal history of cancer. I am what the medical community calls a previvor. The ACA preventive services rule covers previvors with qualifying family histories. To the extent your internal policy excludes them, the policy is narrower than federal law.
Third, the medical reviewer's decision did not address my family history. The reviewer's note, which I received as part of my claim file under 45 CFR 147.136(b)(2)(i)(C), evaluates only the personal-history criterion. My family history of three first- and second-degree relatives with breast or ovarian cancer is not mentioned anywhere in the reviewer's analysis.
What this does. This is the whole argument. Point one establishes what the federal law requires. Point two shows where BHC's policy falls short of the federal law. Point three shows that even by BHC's own narrower policy, the reviewer didn't do the analysis properly. Any single point is enough to overturn. Three of them together is a wall.
C. Supporting documents enclosed
Letter of medical necessity from Dr. Singh, dated June 5, 2026
Letter from the genetic counselor summarizing the risk assessment
USPSTF Final Recommendation Statement on BRCA-Related Cancer (2019)
Family pedigree
Copy of denial letter dated May 10, 2026
Copy of the claim file provided by BHC on May 26, 2026
What this does. Boring on purpose. The letter of medical necessity from Dr. Singh is the most important attachment in the packet. Without it, the reviewer only has Margaret's word. With it, a doctor is on the record saying the test is needed.
D. What I am asking for
I am asking BHC to reverse the denial of claim 87654321 and process the hereditary cancer panel as a covered preventive service under Section 2713 of the ACA, with no cost-sharing.
Under 45 CFR 147.136(b)(2)(ii)(C), if BHC develops new evidence during this appeal, please send it to me in writing and allow me to respond before issuing a final decision.
Under 45 CFR 147.136(b)(2)(ii)(F), please respond within 60 days. If a response is not received by August 8, 2026, I will consider the internal appeal exhausted and proceed directly to external review.
Sincerely,
Margaret T. Corgi
What this does. The ask, in the regulation's own words. The two citations at the end signal two things to BHC. First, Margaret knows about Right 4 (they have to share new evidence with her before deciding). Second, she knows about Right 5 (if they miss the deadline, she skips the line to external review).
What Margaret sends, exactly.
The letter above is the cover letter. Her full packet includes:
The cover letter (the one you just read)
A letter of medical necessity from Dr. Singh
A supporting letter from the genetic counselor
The USPSTF recommendation document
A family pedigree
A copy of the original denial letter
A copy of her claim file from BHC
How she sends it (the realistic 2026 version)
Almost everyone in healthcare uses patient portals now, both insurance companies and doctors' offices. Margaret uses the easiest path first and keeps a paper copy as backup.
To BHC (the insurer):
Primary submission: BHC's member portal. Margaret logs in, uploads the full packet as a PDF, and gets a confirmation case number on screen. She screenshots that screen. This is the fastest and most reliable method; the portal timestamps her submission and routes it into the right queue automatically.
Backup: certified mail with return receipt. She also mails a hard copy to the appeals address on the denial letter. Costs about $10. She gets a postal-stamped receipt as proof. This matters if BHC ever claims they never received the appeal, or if she later needs to escalate to external review or court.
To Dr. Singh (the doctor):
The simplest thing: she uploads the same PDF to Dr. Singh's patient portal as a secure message and brings a hard copy to her next appointment. Both go into her medical record. If his office doesn't have a portal, she emails the office's secure HIPAA email address (most genetic counseling and oncology practices in 2026 have one) or drops a paper copy at the front desk.
The point of getting it to Dr. Singh is two things. First, Dr.Singh's office has the full appeal on file, so if Margaret ever needs them to write a new letter of medical necessity for external review, they have the context. Second, it creates a second written record of the appeal that lives outside BHC's system, which protects Margaret if BHC ever loses or denies receiving her submission.
Total cost: about $10 for the certified mail backup. Everything else is free. She keeps her own digital and paper copies of everything.
A note on sending appeals:
Per HealthCare.gov and CMS guidance, there are four accepted ways to submit an internal appeal. The denial letter should tell you which method to use, usually near the bottom under “How to Appeal.” Margaret’s letter lists a fax number, mailing address, and member portal URL.
The four options, in plain English:
1. The insurer’s secure online portal. Usually the fastest option. It should generate a case number you can reference later. Take a screenshot of the confirmation page.
2. Fax. Still common for appeals intake. Use a fax service that emails you a transmission receipt, then save it as a PDF. Always use the fax number on the denial letter, not the general customer-service page.
3. Certified mail with return receipt. Slower, but gives you postal-stamped proof of delivery. Use it for high-stakes appeals, especially if you may escalate to external review or court.
4. Email. Some insurers allow it, but it is not the federal default. Only use email if the denial letter specifically lists an appeal email address.
The rule is simple: whatever method you choose, keep proof of what you sent, when you sent it, and where you sent it. The proof matters more than the method.
What happens on the other side of the wall
Margaret's portal submission lands in BHC's appeals queue the same day she uploads it. Her certified mail backup arrives two days later and gets matched to the existing case number in the system. The full packet crosses the desk of Otis, the French bulldog in a tan blazer you met in Part 1. He works in member services. He doesn't make the clinical decision, but every appeal that comes in crosses his desk first.
He picks up Margaret's letter. "She references the section we apply, the federal section we have to comply with, and her own claim file. The packet is complete. When something like this comes in under the patient's name, with their signature, the file gets a different kind of attention. The notes get written more carefully, because we know the patient is reading them, and the file might end up in front of an outside reviewer if they escalate."
Otis is not a villain. He's confirming what Part 1 already said. The system pays more attention when the patient is in the room.
The reversal arrives
Six weeks after Margaret sent her letter, an email from BHC lands in her inbox: "A decision has been made on your appeal. Log in to view." She logs into the portal. A two-page PDF is waiting for her. Two days later, the same letter arrives by paper mail in her mailbox.
Here is what the first page actually says:
NOTICE OF APPEAL DECISION
Member: Margaret T. Corgi Claim Number: 87654321 Date of Decision: July 21, 2026
BHC has completed its review of your appeal dated June 9, 2026.
The original adverse benefit determination has been overturned.
The hereditary cancer panel (CPT codes [XXXXX]) will be processed as a covered preventive service under Section 2713 of the Affordable Care Act, with no member cost-sharing. The claim has been reprocessed and payment will be issued to the in-network laboratory.
No further action is required from you at this time.
This is what happens when a patient uses the rights the federal government already gave them. The reason it doesn't happen more often is that almost no one tries. Per KFF's March 2026 report on ACA marketplace plans, fewer than 1% of denials were appealed by members in 2024, and insurers upheld their original decision in 66% of the appeals that were filed.
But look at the other side of that math. In Medicare Advantage in 2024, 80.7% of appealed prior authorization denials were overturned (KFF). Only 11.5% of denied prior auth requests were appealed. Eight out of ten patients who push back, win. Nine out of ten don't push back at all.
If Margaret's appeal had been upheld instead
It happens. Of the marketplace appeals that get filed, insurers uphold their original decision 66% of the time (KFF, March 2026). Margaret could have written a perfect letter and still gotten a second denial.
If that had happened, her next move would have been external review. An independent reviewer, not BHC, looks at her file. Their decision is binding on BHC. Margaret would have had at least four months from the second denial to file under federal law (some states allow longer; California allows 180 days). She would not have rewritten the letter. The argument was already strong. She would have added one new piece of evidence (often a stronger letter from the genetic counselor, citing two or three published studies on clinical utility of BRCA panel testing) and submitted the same packet.
The math at external review is more favorable than at internal appeal. A 2025 Health Affairs study of public Independent Medical Review data from four states found 46% of all genetic testing IMR appeals were overturned. KFF's March 2026 analysis of marketplace plans showed about 30% of denials specifically for cancer genetic tests were overturned at external review.
The third path: if BHC had missed the deadline
This is the move almost nobody uses. Under 45 CFR 147.136(b)(2)(ii)(F), if your insurance company fails to strictly follow the federal claims and appeals process (which includes responding to your appeal within the required deadline), you are "deemed to have exhausted" the internal appeals process. You can go straight to external review. The regulation says it in those exact words.
If BHC had not responded to Margaret by August 8 (60 days after she filed her post-service appeal), she would have written a one-line letter: "Under 45 CFR 147.136(b)(2)(ii)(F), the internal appeal is deemed exhausted. I am proceeding to external review."
She would not have asked permission. She would not have waited. Their missed deadline is her shortcut.
One real-world note: the regulation has a narrow exception for very minor process violations that don't actually harm the claimant (called "de minimis" violations in the rule). The exception is meant for genuine clerical slips, not for missed deadlines or refused document requests. If your insurer missed a real deadline or denied you a document the law requires, the deemed exhaustion right is yours to use.
The plan map: which deadlines apply to you
Margaret had a fully insured employer plan, which is the cleanest version of the rules. Yours might be different. The federal rights at 45 CFR 147.136 are the same for every non-grandfathered plan, but the deadlines and the external review process shift by plan type. Find your card and check which one applies:
ACA marketplace plans. 180 days to file the internal appeal. External review available after a final internal denial.
Fully insured employer plans. Same 180 days. External review goes through your state's process or the federal HHS process if your state doesn't have one.
Self-funded ERISA plans. This is the majority of US employer coverage. Same 180 days. External review applies, but the plan picks the process. The Summary Plan Description (your plan's own rulebook) is binding. Get a copy from HR before you file.
Medicare Advantage. Shorter deadline. 60 days to file, not 180. The appeal auto-forwards to an independent contractor if BHC upholds it. Win rates are very high: 80.7% of appealed prior auth denials were overturned in 2024.
Traditional Medicare. Different system. 120 days to file redetermination. Five levels of federal appeal above that.
Medicaid. State-specific. Most states give 60 to 90 days. External review is usually a state fair hearing.
The urgent track
If waiting for the standard timeline would seriously jeopardize your health, your life, or your ability to recover full function, you don't have to follow it. Under 45 CFR 147.136, you can file the internal appeal and external review at the same time, and the deadlines collapse to 72 hours each (per MAXIMUS Federal External Review FAQ and CMS guidance on expedited reviews).
The trigger phrase when you file is "expedited appeal" or "urgent care appeal." Your doctor signs a short statement attesting to the urgency. Only use this when it's real. Reviewers spot abuse, and a falsely urgent appeal gets bumped to the back of the regular line.
Five mistakes that lose appeals
Margaret avoided all of these. Most people don't.
Writing the letter before reading the policy: The appeal is an argument against a specific document. Without that document, the argument is generic, and generic gets denied again.
Leading with emotion: Family history, specific dates, and policy citations move reviewers. "This is unfair" doesn't.
No letter of medical necessity from the ordering doctor: The most important attachment in the packet. Without it, the reviewer only has the patient's word.
Missing the 180-day deadline: This is the one that ends appeals before they start. 180 days sounds like a long time. It is not. People put the denial letter in a drawer, deal with their lives, and come back to it on day 200 wanting to fight. By then the federal door is closed. Mark the date the day the denial arrives. Put it in your calendar. Set a phone alarm. The deadline is the most important single fact on the page.
Stopping at the internal appeal: First-round internal appeals get upheld 66% of the time at the marketplace level (KFF, March 2026). External review is where the win rate jumps.
You don't have to do this alone
Many states have a Consumer Assistance Program (CAP) or an equivalent state office (such as a state insurance department's consumer help line) whose job is to help with insurance disputes, including filing appeals on your behalf at no cost. CMS confirms that CAPs originally received federal grant funding under Section 1002 of the Affordable Care Act; programs still operating today are funded through other state-level mechanisms.
The official list of where to find your state's help is at cms.gov/cciio/resources/consumer-assistance-grants, and HealthCare.gov maintains a consumer-facing version at healthcare.gov/how-can-i-get-consumer-help-if-i-have-insurance. If your state doesn't have a CAP, the same page directs you to your state Department of Insurance or the U.S. Department of Labor's Employee Benefits Security Administration (1-866-444-3272) for employer-plan questions.
For hereditary cancer denials specifically, FORCE maintains a free public library of sample appeal letters at brca.info, including ones written for BRCA-related denials. Margaret could have started from one of those if she had not wanted to write her own.
For cancer-related denials more broadly, free helplines include the American Cancer Society (1-800-227-2345), the Patient Advocate Foundation (1-800-532-5274), and Triage Cancer (1-424-258-4628).
If you ever feel overwhelmed, one phone call can hand the whole appeal to someone whose job is to win it.
What to do this week
Three things, no denial required. Every link below is a government or official source.
Find your plan type. Check your benefits portal (the one your HR or insurance gives you) or your insurance card. If you have employer coverage, ask HR whether your plan is fully insured or self-funded. This one fact changes which external review track applies. If you can't reach HR, the DOL Employee Benefits Security Administration takes plan-type questions at 1-866-444-3272 or askebsa.dol.gov.
Save the federal appeals resources. HealthCare.gov's appeals overview is at healthcare.gov/appeal-insurance-company-decision. The CMS Consumer Assistance Program map (where to find your state's appeals help) is at cms.gov/cciio/resources/consumer-assistance-grants. The HHS-administered federal external review (used when your state doesn't have a qualifying process, or for ERISA self-funded plans) is administered by MAXIMUS Federal Services at externalappeal.com (1-888-866-6190 for urgent requests).
If you have a past denial sitting unappealed, check the date. If it's within 180 days of the denial (60 for Medicare Advantage), you still have time. Request the three documents from the insurer. Read them. Look for the gap between their internal policy and federal coverage rules or clinical guidelines.
For RCM and market access leaders
If you're a patient, you can stop here, save the issue, and pass it along to anyone who needs it. The rest is for the people who run appeals at scale.
A. For RCM leaders
Two specific changes to how you handle denials.
Your denial recovery rate is being capped by your intake forms. An Assignment of Benefits gets you paid. An Authorized Representative form gives the patient's federal rights to your team for that specific appeal. Under ERISA, AOB rights can be blocked by anti-assignment clauses; Authorized Representative designations generally cannot (per DOL ERISA claims procedure regulation 29 CFR 2560.503-1 and 45 CFR 147.136). Collect both at intake, not just the AOB.
This matters most for ERISA cases and at external review, where standing questions can affect whether the merits of a denial ever get heard. Whether patient-led appeals produce measurably higher win rates than provider-led ones at the internal stage isn't well-quantified in the published literature. What is documented is that external review overturn rates are substantially higher than practice-level internal appeal rates (a 2025 Health Affairs analysis of public IMR data from four states found 46% of all genetic testing IMR appeals were overturned; UCLA Health reported about 25% of appeals approved at the practice level in 2024). The implication: the more cases that reach external review with proper standing, the better the recovered-revenue math tends to look.
Track recovery rate at each stage separately: first-pass, internal appeal, external review. Teams that escalate clinically clean denials to external review tend to see higher recovery rates at that stage than at the internal-appeal-only stage.
B. For market access
This is where appeals data turns into something you can use in payer meetings.
Every appeal produces three pieces of intelligence: which payer denied, which policy version they cited, and how an independent reviewer ruled if it went that far. Build the spreadsheet. After 50 appeals, you have a map. After 200, you have an argument that holds up in a negotiation.
A few specific moves:
Track independent medical review outcomes by payer, state, and test category. Update monthly. Patterns surface within a quarter.
Bring overturn data to payer policy meetings. A policy that loses 60 percent of its independent reviews is a negotiating position. Frame the conversation around alignment with USPSTF, NCCN, or ACMG guidelines.
Use appeal outcomes in coverage advocacy with state regulators. State Departments of Insurance care about IMR overturn rates. A clean dataset showing one payer's policy out of step with clinical guidelines is a regulatory artifact you can hand someone.
Feed appeal patterns back into pre-service strategy. If three payers keep denying for the same documentation gap, fix the gap at intake. The cheapest appeal is the one you never file because the claim went out clean the first time.
Connect appeals to evidence generation. If a clinical guideline gap is driving denials, that gap is also driving your evidence dossier priorities. Real-world appeal data is one of the cleanest sources of payer policy intelligence available, and most market access teams aren't using it.
The goal is to use denial patterns to change payer behavior at the policy level. That moves the floor for every future patient on that plan.
That's it for this issue. Hit reply. I read everything.
Sources
Federal appeal rules and deadlines, 45 CFR 147.136: https://www.law.cornell.edu/cfr/text/45/147.136
DOL ERISA Claims Procedure Rule, 29 CFR 2560.503-1 (incorporated by reference into 45 CFR 147.136 and governing the "full and fair review," the relevant-documents disclosure, and the claim-file access rights): https://www.law.cornell.edu/cfr/text/29/2560.503-1
ACA Section 2713 preventive services coverage: https://www.healthcare.gov/preventive-care-adults/
USPSTF Grading System (Grade A, B, C, D, I): https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions
KFF Claims Denials and Appeals in ACA Marketplace Plans in 2024, March 2026: https://www.kff.org/patient-consumer-protections/claims-denials-and-appeals-in-aca-marketplace-plans-in-2024/
KFF Medicare Advantage Prior Authorization data 2024: https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024/
Health Affairs IMR study, December 2025 (UCSF researchers): https://www.healthaffairs.org/doi/10.1377/hlthaff.2025.00716
HealthCare.gov, How to appeal an insurance company decision: https://www.healthcare.gov/appeal-insurance-company-decision/
CMS Consumer Assistance Program map: https://www.cms.gov/cciio/resources/consumer-assistance-grants
CMS HHS-administered Federal External Review (CCIIO): https://www.cms.gov/cciio/programs-and-initiatives/consumer-support-and-information/csg-ext-appeals-facts
MAXIMUS Federal External Review Process FAQ: https://maximusferp.my.site.com/FERP/s/faq
MAXIMUS Federal External Review: https://externalappeal.com
DOL Employee Benefits Security Administration: https://www.askebsa.dol.gov
DOL ERISA Benefit Claims Procedure FAQs: https://www.dol.gov/agencies/ebsa/about-ebsa/our-activities/resource-center/faqs/benefit-claims-procedure-regulation
FORCE sample appeal letters: https://brca.info/support/insurance-paying-for-care/health-insurance-appeals/sample-appeal-letters
American Cancer Society, If Your Health Insurance Claim Is Denied: https://www.cancer.org/cancer/financial-insurance-matters/managing-health-insurance/if-your-health-insurance-claim-is-denied.html
Patient Advocate Foundation: https://www.patientadvocate.org
Triage Cancer: https://triagecancer.org
Disclaimer: The content published by preimbursed (the "Newsletter") is provided for general informational and educational purposes only and reflects the opinions and commentary of the author. It does not constitute, and should not be relied upon as, medical, legal, financial, tax, insurance, or other professional advice. No physician-patient, attorney-client, fiduciary, or other professional relationship is created by reading the Newsletter or by corresponding with the author. The Newsletter is not a substitute for individualized advice from a qualified professional. Before making any healthcare, coverage, insurance, financial, or legal decision, you should consult your own physician, attorney, benefits administrator, or other licensed advisor and review your specific plan documents, policies, and applicable law. The author is not responsible for any action taken or not taken in reliance on the content herein, and you assume full responsibility for your use of the information provided. Information in the Newsletter is believed to be accurate as of the date of publication and is drawn from the sources cited. Laws, regulations, coverage rules, corporate ownership, market data, and other facts change frequently and may have changed since publication. Certain statements describe pending, recently enacted, or phased-in legal and regulatory changes whose scope, interpretation, and effective dates may shift. The author makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any content, and disclaims all liability for any errors or omissions to the fullest extent permitted by law. References to any company, organization, product, government program, or individual are made solely for purposes of news reporting, commentary, analysis, and criticism, and do not imply any endorsement, sponsorship, affiliation, or partnership. All trademarks, service marks, and trade names are the property of their respective owners and are used only for identification and descriptive purposes. Where a named party disputes a characterization or finding, the Newsletter notes that dispute. Statements concerning identified companies reflect cited reporting and the author's opinion and analysis of matters of public concern. Certain characters, organizations, and scenarios in the Newsletter, including but not limited to Biscuit, Dr. Singh, and composite payer and provider names, are fictional and used for illustration. Any resemblance to actual persons or entities is coincidental.
Disclosure: The authors are the co-founders of Converus.ai, a company that organizes payer policy information for healthcare providers, and therefore has a commercial interest in the subject matter discussed. References to Converus.ai are made only where relevant and are not paid placements. To the fullest extent permitted by applicable law, the author and preimbursed disclaim all warranties and shall not be liable for any direct, indirect, incidental, consequential, or other damages arising out of or in connection with your use of, or reliance on, the Newsletter.
